1 active not recruiting, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Withdrawn 1 |
Follow Bimagrumab Placebo: new trials by email Literature Review of Bimagrumab Placebo trials Research Report on Bimagrumab Placebo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes Bimagrumab, Tirzepatide, Bimagrumab Placebo - Obesity, Overweight | Phase 2 | Withdrawn | Eli Lilly and Company | 2025-05-23 | 2025-09-24 | |
| A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight Bimagrumab, Tirzepatide, Bimagrumab Placebo - Obesity, Overweight | Phase 2 | Active not recruiting | Eli Lilly and Company | 252 | 2024-10-21 | 2026-05-26 |
Obesity (2) · Overweight (2) · Platelet Glycoprotein IV Deficiency (2) · Diabetes Mellitus, Type 2 (1)
United States (2) · Argentina (1) · Canada (1) · China (1) · Japan (1)